皮肌炎皮肤损害的研究进展
|
摘要
皮肌炎和临床无肌病性皮肌炎的皮肤损害与疾病活动性及预后相关,但目前皮肌炎皮损的发生机制尚未完全清楚。了解皮肌炎的皮损特点及发生机制,有助于在临床工作中开展针对皮损的治疗。
Skin lesions of dermatomyositis(DM) and clinical amyopathic dermatomyositis(CADM) are associated with disease activity and prognosis. However,the pathogenesis of skin lesions in dermatomyositis is not fully understood. Recognition of the skin lesions in dermatomyositis is helpful for clinical treatment.
Skin lesions of dermatomyositis(DM) and clinical amyopathic dermatomyositis(CADM) are associated with disease activity and prognosis. However,the pathogenesis of skin lesions in dermatomyositis is not fully understood. Recognition of the skin lesions in dermatomyositis is helpful for clinical treatment.
引文
[1]Cao H,Parikh TN,Zheng J.Amyopathic dermatomyositis or dermatomyositis-like skin disease:retrospective review of16 cases with amyopathic dermatomyositis[J].Clin Rheumatol,2009,28(8):979-984.
[2]Cheong WK,Hughes GR,Norris PG,et al.Cutaneous photosensitivity in dermatomyositis[J].Br J Dermatol,1994,131(2):205-208.
[3]Dourmishev L,Meffert H,Piazena H.Dermatomyositis:comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects[J].Photodermatol Photoimmunol Photomed,2004,20(5):230-234.
[4]De Paepe B,KK C,JJ M,et al.A dual role for HSP90 and HSP70 in the inflammatory myopathies:from muscle fiber protection to active invasion by macrophages[J].Ann N YAcad Sci,2009,1173(1):463-469.
[5]何黎.皮肤屏障与相关皮肤病[J].中华皮肤科杂志,2012,45(6):455-457.
[6]Rpke MA,Alonso C,Jung S,et al.Effects of glucocorticoids on stratum corneum lipids and function in human skin-A detailed lipidomic analysis[J].J Dermatol Sci,2017,88(3):330-338.
[7]Fernandez-Flores A,Cassarino DS.Gottron papules show histopathologic features of localized lymphedema[J].Am JDermatopath,2017,39(7):518-523.
[8]Hornung T,Wenzel J.Innate immune-response mechanisms in dermatomyositis:an update on pathogenesis,diagnosis and treatment[J].Drugs,2014,74(9):981-998.
[9]Wenzel J,Tüting T.An IFN-associated cytotoxic cellular immune response against viral,self-,or tumor antigens is a common pathogenetic feature in"interface dermatitis"[J].J Invest Dermatol,2008,128(10):392-402.
[10]Zahn S,Barchet W,Rehkmper C,et al.Enhanced skin expression of melanoma differentiation-associated gene 5(MDA5)in dermatomyositis and related autoimmune diseases[J].J Am Acad Dermatol,2011,64(5):988-989.
[11]赵云,吕玲.多发性肌炎/皮肌炎病因和发病机制研究进展[J].复旦学报(医学版),2009,36(6):779-781.
[12]Merlo G,Clapasson A,Cozzani E,et al.Specific autoantibodies in dermatomyositis:a helpful tool to classify different clinical subsets[J].Arch Dermatol Res,2017,309(2):87-95.
[13]Ortizsantamaria V,Babot A,Ferrer C.Anti-MDA5-positive dermatomyositis:an emerging entity with a variable clinical presentation[J].Scand J Rheumatol,2017,46(6):509-511.
[14]Cao H,Xia Q,Pan M,et al.Gottron papules and gottron sign with ulceration:a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis[J].J Rheumatol,2016,43(9):1735-1742.
[15]Daly ML,Gordon PA,Creamer D.Cutaneous features of dermatomyositis associated with myositis-specific antibodies[J].Br J Dermatol,2017,176(6):1662-1665.
[16]Sunderk9tter C,Nast A,Worm M,et al.Guidelines on dermatomyositis-excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology[J].J Dtsch Dermatol Ges,2016,14(3):321-38.
[17]Griger Z,Nagy-Vincze M,Danko K.Pharmacological management of dermatomyositis[J].Expert Rev Clin Pharmacol,2017,10(10):1109-1118.
[18]Hornung T,Ko A,Tuting T,et al.Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions[J].Clin Exp Dermatol,2012,37(2):139-142.
[19]Aggarwal R,Loganathan P,Koontz D,et al.Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab[J].Rheumatology(Oxford),2016,56(2):247-254.
[20]Kim JE,Jeong MG,Lee HE,et al.Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus[J].Ann Dermatol,2011,23(3):348-351.
[21]Ge Y,Zhou H,Shi J,et al.The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis:a systematic review[J].Clin Rheumatol,2015,34(12):2097-2103.
[22]Kaveri SV,Lecerf M,Saha C,et al.Intravenous immunoglobulin and immune response[J].Clin Exp Immunol,2014,178(Suppl 1):94-96.
[23]Galimberti F,Li Y,Fernandez AP.Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis[J].J Am Acad Dermatol,2015,73(1):174-176.
[24]Rowe B,Yosipovitch G.Paraneoplastic itch management[J].Curr Probl Dermatol,2016,50:149-54.
[2]Cheong WK,Hughes GR,Norris PG,et al.Cutaneous photosensitivity in dermatomyositis[J].Br J Dermatol,1994,131(2):205-208.
[3]Dourmishev L,Meffert H,Piazena H.Dermatomyositis:comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects[J].Photodermatol Photoimmunol Photomed,2004,20(5):230-234.
[4]De Paepe B,KK C,JJ M,et al.A dual role for HSP90 and HSP70 in the inflammatory myopathies:from muscle fiber protection to active invasion by macrophages[J].Ann N YAcad Sci,2009,1173(1):463-469.
[5]何黎.皮肤屏障与相关皮肤病[J].中华皮肤科杂志,2012,45(6):455-457.
[6]Rpke MA,Alonso C,Jung S,et al.Effects of glucocorticoids on stratum corneum lipids and function in human skin-A detailed lipidomic analysis[J].J Dermatol Sci,2017,88(3):330-338.
[7]Fernandez-Flores A,Cassarino DS.Gottron papules show histopathologic features of localized lymphedema[J].Am JDermatopath,2017,39(7):518-523.
[8]Hornung T,Wenzel J.Innate immune-response mechanisms in dermatomyositis:an update on pathogenesis,diagnosis and treatment[J].Drugs,2014,74(9):981-998.
[9]Wenzel J,Tüting T.An IFN-associated cytotoxic cellular immune response against viral,self-,or tumor antigens is a common pathogenetic feature in"interface dermatitis"[J].J Invest Dermatol,2008,128(10):392-402.
[10]Zahn S,Barchet W,Rehkmper C,et al.Enhanced skin expression of melanoma differentiation-associated gene 5(MDA5)in dermatomyositis and related autoimmune diseases[J].J Am Acad Dermatol,2011,64(5):988-989.
[11]赵云,吕玲.多发性肌炎/皮肌炎病因和发病机制研究进展[J].复旦学报(医学版),2009,36(6):779-781.
[12]Merlo G,Clapasson A,Cozzani E,et al.Specific autoantibodies in dermatomyositis:a helpful tool to classify different clinical subsets[J].Arch Dermatol Res,2017,309(2):87-95.
[13]Ortizsantamaria V,Babot A,Ferrer C.Anti-MDA5-positive dermatomyositis:an emerging entity with a variable clinical presentation[J].Scand J Rheumatol,2017,46(6):509-511.
[14]Cao H,Xia Q,Pan M,et al.Gottron papules and gottron sign with ulceration:a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis[J].J Rheumatol,2016,43(9):1735-1742.
[15]Daly ML,Gordon PA,Creamer D.Cutaneous features of dermatomyositis associated with myositis-specific antibodies[J].Br J Dermatol,2017,176(6):1662-1665.
[16]Sunderk9tter C,Nast A,Worm M,et al.Guidelines on dermatomyositis-excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology[J].J Dtsch Dermatol Ges,2016,14(3):321-38.
[17]Griger Z,Nagy-Vincze M,Danko K.Pharmacological management of dermatomyositis[J].Expert Rev Clin Pharmacol,2017,10(10):1109-1118.
[18]Hornung T,Ko A,Tuting T,et al.Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions[J].Clin Exp Dermatol,2012,37(2):139-142.
[19]Aggarwal R,Loganathan P,Koontz D,et al.Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab[J].Rheumatology(Oxford),2016,56(2):247-254.
[20]Kim JE,Jeong MG,Lee HE,et al.Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus[J].Ann Dermatol,2011,23(3):348-351.
[21]Ge Y,Zhou H,Shi J,et al.The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis:a systematic review[J].Clin Rheumatol,2015,34(12):2097-2103.
[22]Kaveri SV,Lecerf M,Saha C,et al.Intravenous immunoglobulin and immune response[J].Clin Exp Immunol,2014,178(Suppl 1):94-96.
[23]Galimberti F,Li Y,Fernandez AP.Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis[J].J Am Acad Dermatol,2015,73(1):174-176.
[24]Rowe B,Yosipovitch G.Paraneoplastic itch management[J].Curr Probl Dermatol,2016,50:149-54.